Sugi Predict

Sugi Predict / Targets / ING2

ING2

Inhibitor of growth protein 2 · Q9H160 · ING2 on Sugi Atlas →

1,073 patent compounds predicted against ING2, 730 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15397115 SCHEMBL15397115 1.00 3/20
SCHEMBL15397119 SCHEMBL15397119 1.00 3/20
SCHEMBL19203101 SCHEMBL19203101 1.00 3/20
SCHEMBL19818223 SCHEMBL19818223 1.00 3/20
SCHEMBL19817546 SCHEMBL19817546 0.89 3/20
SCHEMBL19817553 SCHEMBL19817553 0.89 3/20
SCHEMBL19196161 SCHEMBL19196161 0.81 3/20
SCHEMBL19196167 SCHEMBL19196167 0.81 3/20
SCHEMBL22828087 SCHEMBL22828087 0.81 3/20
SCHEMBL21119108 SCHEMBL21119108 0.75 3/20
SCHEMBL24131677 SCHEMBL24131677 0.75 3/20
SCHEMBL18538249 SCHEMBL18538249 0.73 3/20
SCHEMBL18538247 SCHEMBL18538247 0.70 3/20
SCHEMBL18538283 SCHEMBL18538283 0.68 3/20
SCHEMBL18538301 SCHEMBL18538301 0.68 3/20
SCHEMBL18538303 SCHEMBL18538303 0.68 3/20
SCHEMBL19762894 SCHEMBL19762894 0.68 3/20
SCHEMBL18538312 SCHEMBL18538312 0.62 3/20
SCHEMBL18538304 SCHEMBL18538304 0.60 3/20
SCHEMBL18538306 SCHEMBL18538306 0.60 3/20

Clinical trials — most relevant to ING2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma PHASE2WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma PHASE2UNKNOWN
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
9-ING-41 in Patients With Advanced Cancers PHASE2ACTIVE_NOT_RECRUITING
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Pappalysin 2 (PAPP-A2) Enzyme Replacement PHASE1COMPLETED
KRAS Wild-type Metastatic Colorectal Cancer Trial PHASE1COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma PHASE1COMPLETED
Concentration and Activity of Lapatinib in Vestibular Schwannomas EARLY_PHASE1COMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Genetic Analysis of Familial Melanoma nanCOMPLETED
Molecular Modulation of the Growth Plate nanENROLLING_BY_INVITATION
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Adipocytokines in Endometrial Cancer nanCOMPLETED
Genetic Physiopathology and Evolution of Type 2 Diabetes nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ING2 binder may also engage these)

ProteinNameSimilarity
Q9ESK4 — 1.000 Q9ESK4 →
P38806 — 0.999 P38806 →
Q9QXV3 — 0.998 Q9QXV3 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.996 landscape →
Q8WML3 — 0.995 Q8WML3 →
B3H615 — 0.995 B3H615 →
Q5TKR9 — 0.995 Q5TKR9 →
O74736 — 0.993 O74736 →
Q92539 — 0.993 Q92539 →
Q757W2 — 0.993 Q757W2 →
Q60MF5 — 0.993 Q60MF5 →
Q17QK1 — 0.993 Q17QK1 →
G5EFD2 — 0.993 G5EFD2 →
A6QP06 — 0.993 A6QP06 →
Q99PI5 — 0.992 Q99PI5 →
Q6FSB1 — 0.992 Q6FSB1 →
Q24K09 — 0.992 Q24K09 →
A8KBE0 — 0.992 A8KBE0 →
Q9VJY8 — 0.992 Q9VJY8 →
Q28D84 — 0.992 Q28D84 →
Q20548 — 0.992 Q20548 →
Q9CSP9 — 0.992 Q9CSP9 →
A7YDW0 — 0.992 A7YDW0 →
Q5SVQ0 — 0.992 Q5SVQ0 →
F4K4J0 — 0.992 F4K4J0 →
KAT7 Histone acetyltransferase KAT7 0.992 landscape →
B4HEJ6 — 0.992 B4HEJ6 →
Q8C0I4 — 0.992 Q8C0I4 →
Q6E3D4 — 0.992 Q6E3D4 →
Q4V863 — 0.992 Q4V863 →